 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 July 1997 | Volume 127 Issue 2 | Pages 133-137
Background: Visceral leishmaniasis (kala-azar) is a world-wide, disseminated intracellular protozoal infection for which prolonged, conventional therapy with pentavalent antimony has become increasingly less effective.
Objective: To determine the efficacy and minimal effective dose of short-course therapy with amphotericin B lipid complex in visceral leishmaniasis.
Design: A randomized, open-label study.
Setting: Inpatient kala-azar treatment unit in the state of Bihar in northeast India, where visceral leishmaniasis is endemic.
Patients: 60 patients with active infection who had not responded to or who had relapse after receiving conventional (>30 days) treatment with pentavalent antimony.
Intervention: Intravenous amphotericin B lipid complex was given once daily for 5 consecutive days by 2-hour infusion. Patients were randomly assigned to receive 1, 2, or 3 mg/kg of body weight per day (total doses of 5, 10, or 15 mg/kg, respectively).
Measurements: Clinical and parasitologic responses (the latter were measured by parasite density score of the splenic aspirate) were determined 14 days after treatment. Definitive responses were assessed 6 months after treatment according to clinical outcomes and findings on examination of bone marrow aspirate.
Results: All 60 patients responded to 5 days of treatment. Fourteen days after therapy, all patients had parasite-free splenic aspirates and were considered to have an apparent clinical and parasitologic response. Six months after therapy, definitive responses were documented in 16 of 19 (84% [95% CI, 60% to 97%]), 18 of 20 (90% [CI, 68% to 99%]), and 21 of 21 (100% [CI, 84% to 100%]) patients who received total doses of 5, 10, and 15 mg/kg, respectively.
Conclusion: Short-course therapy with low-dose amphotericin B lipid complex is effective for visceral leishmaniasis and is an important therapeutic alternative in the management of this serious intracellular protozoal infection.
Author and Article Information
From Banaras Hindu University, Varanasi, India; The Liposome Co., Princeton, New Jersey; and Cornell University Medical Center, New York, New York.
ABROAD
Short-Course, Low-Dose Amphotericin B Lipid Complex Therapy for Visceral Leishmaniasis Unresponsive to Antimony
Requests for Reprints: Henry W. Murray, MD, Department of Medicine, The New York Hospital-Cornell Medical Center, Box 130, 525 East 68th Street, New York, NY 10021.
Current Author Addresses: Drs. Sundar, Agrawal, and Sinha: Banaras Hindu University, Institute of Medical Sciences, Department of Medicine, Varanasi 221 005, India.
This article has been cited by other articles:
|
|
 |
|
  S. Pal, R. Ravindran, and N. Ali Combination Therapy Using Sodium Antimony Gluconate in Stearylamine-Bearing Liposomes against Established and Chronic Leishmania donovani Infection in BALB/c Mice Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3591 - 3593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lopez-Velez, S. Videla, M. Marquez, V. Boix, M. E. Jimenez-Mejias, M. Gorgolas, J. R. Arribas, A. Salas, F. Laguna, M. Sust, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients J. Antimicrob. Chemother., March 1, 2004; 53(3): 540 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Laguna, S. Videla, M. E. Jimenez-Mejias, G. Sirera, J. Torre-Cisneros, E. Ribera, D. Prados, B. Clotet, M. Sust, R. Lopez-Velez, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study J. Antimicrob. Chemother., September 1, 2003; 52(3): 464 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sundar, G Agrawal, M. Rai, M K Makharia, H. W Murray, and D. N J Lockwood Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial Commentary: cost and resistance remain issues BMJ, August 25, 2001; 323(7310): 419 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Murray Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2185 - 2197. [Full Text] [PDF]
|
|
|
|
|
|
S. Espuelas, P. Legrand, P. M. Loiseau, C. Bories, G. Barratt, and J. M. Irache In Vitro Reversion of Amphotericin B Resistance in Leishmania donovani by Poloxamer 188 Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2190 - 2192. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. W. Murray and S. Delph-Etienne Roles of Endogenous Gamma Interferon and Macrophage Microbicidal Mechanisms in Host Response to Chemotherapy in Experimental Visceral Leishmaniasis Infect. Immun., January 1, 2000; 68(1): 288 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Martino, M. Subira, A. Sureda, and J. Sierra Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies J. Antimicrob. Chemother., October 1, 1999; 44(4): 569 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Petit, V. Yardley, F. Gaboriau, J. Bolard, and S. L. Croft Activity of a Heat-Induced Reformulation of Amphotericin B Deoxycholate (Fungizone) against Leishmania donovani Antimicrob. Agents Chemother., February 1, 1999; 43(2): 390 - 392. [Abstract] [Full Text]
|
|
|
|
|
|
T K Jha, P Olliaro, C P N Thakur, T P Kanyok, B L Singhania, I J Singh, N K P Singh, S Akhoury, S Jha, and D. N J Lockwood Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India • Commentary: Some good news for treatment of visceral leishmaniasis in Bihar BMJ, April 18, 1998; 316(7139): 1200 - 1205. [Abstract] [Full Text]
|
|
Article
